Melanoma News and Research

Latest Melanoma News and Research

Promising melanoma drug demonstrates potential for non-small cell lung cancer treatment

An experimental new cancer drug called MK-3475, which has shown dramatic promise for treating melanoma is also showing early potential as an effective treatment for patients with non-small cell lung cancer, the leading cause of cancer death of men and women worldwide.

30 Oct 2013

Physician treatment perceptions in actinic keratosis: an interview with Kim Kjøller, Senior Vice President for Global Development, LEO Pharma

Firstly, actinic keratosis (AK) is a common dermatological condition caused by cumulative exposure to the sun. Providing patients with effective treatment is very important, as AK can lead to forms of non-melanoma skin cancer (NMSC) if not diagnosed and treated early. In fact, two in three cases of squamous cell carcinoma (a common form of skin cancer), begin as AK.

29 Oct 2013

Dermatologists provide list of specific treatments, procedures not required for medical care

The American Academy of Dermatology today released its list of specific treatments and procedures related to skin health and care that are not always necessary.

29 Oct 2013

Polaris Group reports positive results from ADI-PEG 20 Phase 2 trial for malignant pleural mesothelioma

Polaris Group announced today that positive results from a randomized Phase 2 trial of ADI-PEG 20, arginine deiminase formulated with polyethylene glycol, for the treatment of malignant pleural mesothelioma were presented at the World Conference on Lung Cancer in Sydney, Australia.

28 Oct 2013

Functional biomarker could help guide treatment of patients with BRAF-mutant melanomas

A functional biomarker that can predict whether BRAF-mutant melanomas respond to drugs targeting BRAF could help guide the treatment of patients with these cancers, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19 - 23.

23 Oct 2013

New MDx prototype platform can detect BRAF V600 mutations in 90 minutes

A new diagnostic platform to detect BRAF mutations in melanoma and other cancer types is faster and more accurate compared with the standard method currently used in clinics, and this could help accelerate diagnosis and treatment, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

23 Oct 2013

FDA grants orphan drug designation to Aduro's CRS-207 for treatment of pancreatic cancer

Aduro BioTech, Inc. announced today that the Office of Orphan Products Development of the Food and Drug Administration has granted orphan drug designation for CRS-207, a novel immunotherapy, for the treatment of pancreatic cancer.

22 Oct 2013

AstraZeneca begins selumetinib Phase 3 clinical trial in NSCLC patients

AstraZeneca today announced the first patient randomized in a Phase 3 clinical trial for selumetinib, an oral, potent, selective MEK inhibitor, being investigated as second-line therapy in patients with advanced or metastatic non-small-cell lung cancer whose tumors are KRAS mutation-positive.

22 Oct 2013

New small-molecule inhibitor shows promising results in drug-resistant melanoma, breast cancer

LEE011, a small-molecule inhibitor of cyclin-dependent kinases (CDK) 4/6 being developed by Novartis Oncology, showed promising results in drug-resistant melanoma and drug-resistant breast cancer when tested in combination with other targeted therapies, and based on these preclinical results, several phase I clinical trials were launched recently, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October 19-23.

21 Oct 2013

Wnt5A signaling pathway helps researchers determine who may respond to BRAF inhibitors

One of the challenges of understanding cancer is trying to determine the mechanisms that drive metastasis, or the process by which tumor cells are able to spread throughout the body.

19 Oct 2013

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adults with active ankylosing spondylitis.

18 Oct 2013

Women diagnosed with breast cancer are 39% more likely to develop second cancer

Women diagnosed with invasive breast cancer are 39% more likely to develop a second cancer in a different part of the body. Such is the conclusion of a recent study, pioneered by female Spanish researchers.

18 Oct 2013

Resveratrol can make tumor cells more susceptible to radiation treatment

A recent study by a University of Missouri researcher shows that resveratrol, a compound found in grape skins and red wine, can make certain tumor cells more susceptible to radiation treatment. This research, which studied melanoma cells, follows a previous MU study that found similar results in the treatment of prostate cancer.

12 Oct 2013

Research delves deeply into genomics of glioblastoma multiforme cases to better target disease

When The Cancer Genome Atlas launched its massively collaborative approach to organ-by-organ genomic analysis of cancers, the brain had both the benefit, and the challenge, of going first.

11 Oct 2013

Oncosec Medical reports encouraging results from combination study on aggressive melanoma

OncoSec Medical Inc., a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors, has announced positive preliminary animal data demonstrating the benefits of combining the company's ImmunoPulse with anti-CTLA4 and anti-PD1 antibodies.

9 Oct 2013

Research: Sunscreen provides 100% protection against skin cancer

Next time your kids complain about putting on sunscreen, tell them this: Sunscreen shields a superhero gene that protects them from getting cancer.

9 Oct 2013

MRFBC launches clinical trial to assess impact of bevacizumab and vemurafenib in melanoma patients

The Melanoma Research Foundation Breakthrough Consortium has launched a new clinical trial to assess the impact of concomitant administration of bevacizumab (Avastin) with vemurafenib (Zelboraf) in patients with BRAFV600 mutation positive metastatic melanoma.

8 Oct 2013

New study highlights that physicians prefer topical therapies for actinic keratosis

Over 90 per cent of physicians treating actinic keratosis (AK) prefer short duration treatment options with fast resolving local skin responses (LSRs), is the finding of a global study (‘Physician Perceptions and Experience of Current Treatment in Actinic Keratosis’) that is being presented today at the 22nd Congress of the European Academy of Dermatology and Venereology (EADV).

5 Oct 2013

Trial to determine effectiveness of sun protection program for children of melanoma survivors

Children of melanoma survivors were more likely to wear hats and re-apply sunscreen after receiving a multi-media informational program designed specifically for them. These new findings were included in research published in the journal of Cancer Epidemiology, Biomarkers and Prevention - a publication of the American Association for Cancer Research.

5 Oct 2013

Huntsman investigator receives $1.5M to focus on c-KIT gene's role in melanoma

The National Cancer Institute (NCI) has awarded Huntsman Cancer Institute investigator Matt VanBrocklin, Ph.D., more than $1.5 million over the next five years to continue studying the role of a gene called c-KIT in the origin and growth of melanoma, a devastating and sometimes deadly skin cancer.

1 Oct 2013

Melanoma News and Research

Latest Melanoma News and Research

Promising melanoma drug demonstrates potential for non-small cell lung cancer treatment

Physician treatment perceptions in actinic keratosis: an interview with Kim Kjøller, Senior Vice President for Global Development, LEO Pharma

Dermatologists provide list of specific treatments, procedures not required for medical care

Polaris Group reports positive results from ADI-PEG 20 Phase 2 trial for malignant pleural mesothelioma

Functional biomarker could help guide treatment of patients with BRAF-mutant melanomas

New MDx prototype platform can detect BRAF V600 mutations in 90 minutes

FDA grants orphan drug designation to Aduro's CRS-207 for treatment of pancreatic cancer

AstraZeneca begins selumetinib Phase 3 clinical trial in NSCLC patients

New small-molecule inhibitor shows promising results in drug-resistant melanoma, breast cancer

Wnt5A signaling pathway helps researchers determine who may respond to BRAF inhibitors

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

Women diagnosed with breast cancer are 39% more likely to develop second cancer

Resveratrol can make tumor cells more susceptible to radiation treatment

Research delves deeply into genomics of glioblastoma multiforme cases to better target disease

Oncosec Medical reports encouraging results from combination study on aggressive melanoma

Research: Sunscreen provides 100% protection against skin cancer

MRFBC launches clinical trial to assess impact of bevacizumab and vemurafenib in melanoma patients

New study highlights that physicians prefer topical therapies for actinic keratosis

Trial to determine effectiveness of sun protection program for children of melanoma survivors

Huntsman investigator receives $1.5M to focus on c-KIT gene's role in melanoma

Innovation in neuroscience drug discovery - eBook eBook

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Evolving spectrophotometry for modern biopharma workflows

Melanoma News and Research

Latest Melanoma News and Research

Innovation in neuroscience drug discovery - eBook eBook

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Evolving spectrophotometry for modern biopharma workflows

Newsletters you may be interested in